Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease;Efectividad del tratamiento con paricalcitol por vía oral en pacientes con enfermedad renal crónica en etapas anteriores a la diálisis

Nefrologia

Volumn 31, Issue 6, 2011, Pages 697-706

  Hervas Sanchez J G ^a   Prados Garrido, M D ^a   Polo Moyano, A ^a   Cerezo Morales, S ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Chronic kidney diseases; Paricalcitol; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; ERGOCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS;

AGED; ARTICLE; BIOASSAY; BLOOD; BODY MASS; CHRONIC DISEASE; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG SCREENING; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; HYPERCALCEMIA; KIDNEY DISEASE; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; CALCIUM; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; ENDPOINT DETERMINATION; ERGOCALCIFEROLS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84858318642     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2011.Aug.11030     Document Type: Article

References (34)

1. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994;23:229-36.
2. Khan S. Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease. Am J Med Sci 2007;333:201-7.
3. Levin A, Bakris GL, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of anormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8.
4. Martínez I, Saracho R, Montenegro J, Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996;11(Suppl 3):22-8.
5. Felsenfeld AJ, Rodríguez M. Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective. J Am Soc Nephrol 1999;10:878-90.
6. González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004;24:503-10.
7. Prie D, Torres PU, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009;75:882-9.
8. Isakova T, Gutiérrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 2009;76:705-16.
9. Friedman EA. Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int 2005;(Suppl):S1-S7.
10. Michael M, García D. Secondary hyperparathyroidism in chronic kidney disease: clinical consequences and challenges. Nephrol Nurs J 2004;31:185-94.
11. Malluche HH, Ritz E, Range HP. Bone histology in incipient and advanced renal failure. Kidney Int 1976;9:355-62.
12. Coen G, Mazzaferro G, Ballanti P. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 1996;11:813-9.
13. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009;75:890-7.
14. Mittman N, Desiraju B, Meyer KB, Chattopadhyay J, Avram M. treatment of secondary hyperparathyroidism in ESDR: a 2-year, singlecenter crossover study. Kidney Int 2010;78(Suppl 117):S33-S36.
15. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003;23:369-79.
16. Goldenberg MM. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Clin Ther 1999;21:432-41.
17. Cozzolino M, Brancaccio D. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism. Expert Opin Pharmacother 2008;9:947-54.
18. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001;56:315-23.
19. Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427-32.
20. Cardús A, Panizo S, Parisi E, Fernández E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860-6.
21. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72:709-15.
22. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroi-dism in stages 3 and 4 CKD. Am J Kidney Dis 2006;47:263-76.
23. Teng M, Wolf M, Lowrie E. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56.
24. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY; John Willey and Sons,1989:989.
25. Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 2008;28:97-106.
26. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriolresistant secondary hyperparathyroidism. Am J Kidney Dis 2001;38:S45-S50.
27. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490.
28. Segura P, Borrego FJ, Sánchez-Perales MC, García MJ, Biechy MM, Pérez V. Análisis de la eficacia y de los factores que influyen en la respuesta del hiperparatiroidismo secundario de pacientes en hemodiálisis al cinacalcet. Nefrologia 2010;30(4):443-51.
29. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl. 3):S1-S201.
30. Torregrosa JV, Cannata J, Bover J. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica. Nefrologia 2011;31(Supl 1):3-32.
31. Al Aly Z, González EA, Martin KJ, Gellens ME. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 2004;24(4):422-6.
32. Bover J, Górriz JL, Nieto J, De Francisco ALM, Barril G, Martínez-Castelao A, et al. ¿Hemos mejorado el controlde las alteraciones del metabolismo mineral y óseo en los últimos tres años? Análisis de los datos de los estudios OSERCE I y OSERCE II. Nefrologia 2010;30(Supl 1):46.
33. Peña, M, Prados D, Mañero C, López Hidalgo R, Hervás JG, Cerezo S, et al. Estudio multicéntrico del estado del metabolismo mineral y óseo en pacientes en hemodiálisis en Andalucía 2004-2009. Nefrologia 2010;30(Supl 1):42.
34. Mazzaferro S, Brancaccio D, Messa P, Andeucci VE. Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey. J Nephrol 2011;24(2):225-35.